Molecular Docking Reveals the Binding Modes of Ant... - BV FAPESP
Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Molecular Docking Reveals the Binding Modes of Anticancer Alkylphospholipids and Lysophosphatidylcholine within the Catalytic Domain of Cytidine Triphosphate: Phosphocholine Cytidyltransferase

Texto completo
Autor(es):
Neto, Xisto Antonio de Oliveira [1] ; Alves, Anna Carolina Schneider [1, 2] ; Dias Junior, Reinaldo Antonio [3] ; Rodrigues, Ricardo Pereira [4] ; Lancellotti, Marcelo [1, 2] ; Almeida, Wanda Pereira [1, 2] ; Kawano, Daniel Fabio [3, 1, 2]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Campinas UNICAMP, Fac Pharmaceut Sci, BR-13083871 Campinas, SP - Brazil
[2] Rodrigues, Ricardo Pereira, Univ Espirito Santo UFES, Hlth Sci Ctr CCS, Dept Pharmaceut Sci, BR-29047105 Vitoria, ES, Brazil.Neto, Xisto Antonio de Oliveira, Univ Campinas UNICAMP, Fac Pharmaceut Sci, BR-13083871 Campinas, SP - Brazil
[3] Univ Campinas UNICAMP, Inst Chem, BR-13083970 Campinas, SP - Brazil
[4] Univ Espirito Santo UFES, Hlth Sci Ctr CCS, Dept Pharmaceut Sci, BR-29047105 Vitoria, ES - Brazil
Número total de Afiliações: 4
Tipo de documento: Artigo Científico
Fonte: EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY; v. 122, n. 7 JUN 2020.
Citações Web of Science: 0
Resumo

Alkylphospholipids are synthetic analogues of endogenous phosphatidylcholines with a remarkable ability: induce the selective apoptosis of exponentially growing tumor cells. One hypothesis concerning their mechanism of action is the inhibition of cytidine triphosphate:phosphocholine cytidyltransferase (CCT), which would significantly suppress the phosphatidylcholine biosynthesis to trigger apoptosis. Herein, homology modeling, docking simulations, and the analyses of molecular interaction fields are used to suggest the most probable binding modes of four alkylphospholipids (edelfosine, erucylphosphocholine, perifosine, and miltefosine) and lysophosphatidylcholine at the catalytic domain of human CCT. All compounds display bind modes in agreement with the corresponding groups found in the CCT substrate, phosphocholine, while their binding strengths are increased because of the interaction of the alkyl chains with hydrophobic residues from the M domain of the protein. Analyses of the geometry of the CCT binding-site also suggest that small groups, such as benzyl/2-phenylethyl ethers or equivalent heterocycles, could replace the O-methyl group in edelfosine to yield even better inhibitors. It is believed this study can guide the development of new alkylphospholipids with an improved profile for the inhibition of phosphatidylcholine biosynthesis, a critical component for cell cycle progression that can be explored in cancer chemotherapy. Practical Applications: Studies focusing on the interactions between small ligands and their protein targets are decisive for the comprehension of how conformational changes in the macromolecular structure dictates the biological activity and, consequently, how they can be explored in drug discovery. Most of the current studies on alkylphospholipids focuses on their physicochemical interactions with cholesterol and sphingolipids in lipid rafts that, because of the variability and complexity of the membrane phases, hardly can provide structural data in the X-ray crystallography assays necessary for molecular modeling studies. Therefore, by exploring the inhibition of human cytidine triphosphate:phosphocholine cytidyltransferase as an alternative and, probably, complementary hypothesis to the membrane rafts, a helpful strategy can be provided to overcome the clinical limitations of alkylphospholipids. (AU)

Processo FAPESP: 18/08585-1 - Planejamento e síntese de novos fosfolipídios capazes de induzir seletivamente a apoptose de células tumorais pela atuação em "lipid rafts"
Beneficiário:Daniel Fábio Kawano
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 18/22817-2 - Síntese de novos fosfolipídios antitumorais inibidores da enzima trifosfato de citidina (CTP): fosfocolina citidililtransferase humana
Beneficiário:Xisto Antonio de Oliveira Neto
Modalidade de apoio: Bolsas no Brasil - Mestrado
Processo FAPESP: 17/05876-2 - Planejamento e síntese de novos fosfolipídios capazes de induzir seletivamente a apoptose de células tumorais pela atuação em lipid rafts
Beneficiário:Anna Carolina Schneider Alves
Modalidade de apoio: Bolsas no Brasil - Doutorado